CompletedPhase 2NCT03267303

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy

Studying Narcolepsy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Taisho Pharmaceutical Co., Ltd.
Principal Investigator
Shigeru Okuyama
Taisho Pharmaceutical Co., Ltd.
Intervention
TS-091 5mg(drug)
Enrollment
53 target
Eligibility
16-64 years · All sexes
Timeline
2017 – 2019

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03267303 on ClinicalTrials.gov

Other trials for Narcolepsy

Additional recruiting or active studies for the same condition.

See all trials for Narcolepsy →

← Back to all trials